



## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 21 February 2023.

I am pleased to confirm the following.

## Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)-21
- Abemaciclib + Fulvestrant Less than 5
- Alpelisib + Fulvestrant Less than 5
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent-0
- Atezolizumab + Nab-paclitaxel/Paclitaxel-0
- Capecitabine as a single agent- 15
- Eribulin as a single agent or in combination Less than 5
- Everolimus + Exemestane
- Fulvestrant as a single agent-0
- Lapatinib-0
- Neratinib-0
- Parp Inhibitors (Olaparib/Talazoparib)-Less than 5
- Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)- 19
- Palbociclib + Fulvestrant-0
- Pembrolizumab- Less than 5
- Platinum (e.g. carboplatin or cisplatin) as a single agent-0
- Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)-12
- Ribociclib + Fulvestrant- 19
- Sacituzumab Govitecan- Less than 5
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 9
- Taxane and/or Anthracycline in combination: 69
- Trastuzumab as a single agent or in combination- 59
- Trastuzumab emtansine- Less that 5
- Transtuzumab deruxtecan Less than 5
- Any other active systemic anti-cancer therapy:
  - Platinum in combination Less than 5
  - o Tucatinib- Less than 5
  - vinorelbine-Less than 5
  - Zoledronic acid-87

## Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:

Early/locally advanced breast cancer (Stages 1 to 3B) - This is exempt under section 40 of the Freedom of Information Act – Personal Information – this would involve searching through large amounts of patient medical records.

Advanced/metastatic breast cancer (Stages 3C and 4)- This is exempt under section 40 of the Freedom of Information Act – Personal Information – this would involve searching through large amounts of patient medical records.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.